Genasense, which is used in combination with chemotherapy, works by targeting a key "cell suicide" gene called bcl-2 and then inducing cancer cells to kill themselves.
The bad version of the gene appears to boost osteoporosis risk by limiting the production of the BMP-2 protein, a key molecular stimulator of bone growth, says Dr. Stefansson.